A Phase 3 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 7th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 2nd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2006, is one of 11 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.
This is a Phase 3, randomized, double-blind, placebo-controlled, safety and efficacy study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). Approximately 320 patients at approximately 50 centers will be randomly assigned (1:1) to receive pirfenidone 2403 milligrams or placebo equivalent administered in divided doses three times per day (TID) with food. The primary outcome variable will be the absolute change in percent predicted Forced Vital Capacity from Baseline to Week 72. Patients will be randomized by geographic region.
Patients will receive blinded study treatment from the time of randomization until the last patient randomized has been treated for 72 weeks. A Data Monitoring Committee (DMC) will periodically review safety and efficacy data to ensure patient safety.
After week 72, patients who meet the Progression of Disease (POD) definition, which is a ≥ 10% absolute decrease in percent predicted Forced Vital Capacity or a ≥ 15% absolute decrease in percent predicted carbon monoxide diffusing capacity (DLco), will be eligible to receive permitted idiopathic pulmonary fibrosis therapies in addition to their blinded study drug. Permitted idiopathic pulmonary therapies include corticosteroids, azathioprine, cyclophosphamide and N-acetyl-cysteine (with restrictions).
Primary Inclusion criteria:
Primary Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2403 mg/day pirfenidone dose group.
Drug: Pirfenidone
Placebo equivalent.
Drug: Placebo
2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Absolute Change in Percent Predicted Forced Vital Capacity(FVC)
Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.
Time frame: Baseline to week 72
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.
Time frame: Baseline to week 72
Progression-free Survival
Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.
Time frame: Baseline to Week 72
Change in the Six-Minute Walk Test (6MWT) Distance
The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).
Time frame: Baseline to Week 72
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test
The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.
Time frame: Baseline to Week 72
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.
Time frame: Baseline to Week 72
Change in Dyspnea Score
The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.
Time frame: Baseline to Week 72
Worsening of IPF
Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.
Time frame: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.
| Milestone | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Started | 171 | 173 |
| Completed | 137 | 142 |
| Not completed | 34 | 31 |
Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.
| Change in Percent Predicted FVC | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Absolute Change in Percent Predicted Forced Vital Capacity(FVC) | -9 ± 19.58 | -10 ± 19.12 |
Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.
| Patients | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Decline >=20% or death or lung transplantation | 20 | 23 |
| Decline <20% but >= 10% | 19 | 23 |
| Decline <10% but > 0% | 88 | 89 |
| Improvement of >=0% but <10% | 41 | 33 |
| Improvement of >=10% | 3 | 5 |
Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.
| Number of Patients with Progression | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Death or Disease Progression | 54 | 60 |
| Decline in percent predicted FVC >=10% | 31 | 41 |
| Decline in percent predicted DLco >=15% | 10 | 9 |
| Death Before Disease Progression | 13 | 10 |
The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).
| Change in Distance Walked in Meters | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Change in the Six-Minute Walk Test (6MWT) Distance | -45 ± 140 | -77 ± 128 |
The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.
| Change,Worst Oxygen Saturation (Percent) | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test | -1.9 ± 3.83 | -1.3 ± 6.63 |
The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.
| Change in Percent Predicted DLco | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs | -9.8 ± 12.61 | -9.2 ± 13.24 |
The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.
| Change in Dyspnea Score | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Change in Dyspnea Score | 11.9 ± 24.72 | 13.9 ± 27.89 |
Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.
| Number of Patients Who Worsened | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Woresening IPF | 24 | 32 |
| Acute IPF exacerbation | 2 | 1 |
| IPF-related death | 3 | 6 |
| Lung transplantation | 2 | 2 |
| Respiratory hospitalization | 17 | 23 |
| Patients Censored | 146 | 141 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone (2403 mg/d) | — | 53/171 (31%) | 169/171 (98.8%) |
| Placebo | — | 51/173 (29.5%) | 170/173 (98.3%) |
| Event | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| Idiopathic Pulmonary FibrosisRespiratory, thoracic and mediastinal disorders | 13/171 | 17/173 |
| Lobar PneumoniaInfections and infestations | 7/171 | 7/173 |
| Coronary Artery DiseaseCardiac disorders | 6/171 | 0/173 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 4/171 | 6/173 |
| BronchitisInfections and infestations | 0/171 | 5/173 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 2/171 | 3/173 |
| Atrial FibrillationCardiac disorders | 2/171 | 1/173 |
| Sick Sinus SyndromeCardiac disorders | 2/171 | 0/173 |
| ColitisGastrointestinal disorders | 2/171 | 0/173 |
| FallInjury, poisoning and procedural complications | 2/171 | 1/173 |
| Event | Pirfenidone (2403 mg/d) | Placebo |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 58/171 | 22/173 |
| CoughRespiratory, thoracic and mediastinal disorders | 51/171 | 54/173 |
| Idiopathic Pulmonary FibrosisRespiratory, thoracic and mediastinal disorders | 31/171 | 40/173 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 28/171 | 34/173 |
| DizzinessNervous system disorders | 30/171 | 18/173 |
| HeadacheNervous system disorders | 28/171 | 25/173 |
| Back PainMusculoskeletal and connective tissue disorders | 21/171 | 15/173 |
| AnorexiaMetabolism and nutrition disorders | 18/171 | 6/173 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 17/171 | 4/173 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/171 | 11/173 |
| Age, Categorical(Participants) | Pirfenidone (2403 mg/d) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 70 | 61 | 131 |
| >=65 years | 101 | 112 | 213 |
| Age, Continuous(years) | Pirfenidone (2403 mg/d) | Placebo | Total |
|---|---|---|---|
| Mean | 66.8 ± 7.90 | 67.0 ± 7.80 | 66.9 ± 7.84 |
| Sex: Female, Male(Participants) | Pirfenidone (2403 mg/d) | Placebo | Total |
|---|---|---|---|
| Female | 48 | 49 | 97 |
| Male | 123 | 124 | 247 |
| Region of Enrollment(participants) | Pirfenidone (2403 mg/d) | Placebo | Total |
|---|---|---|---|
| United States | 148 | 150 | 298 |
| Europe | 23 | 22 | 45 |
| Australia | 0 | 1 | 1 |
The record gives a start of Apr 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 7 months after primary completion. A results delay was requested in Aug 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
Idiopathic Pulmonary Fibrosis →